Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE - San-Miguel, Jesus; Avet-Loiseau, Hervé; Paiva, Bruno; Kumar, Shaji; Dimopoulos, Meletios A.; Facon, Thierry; Mateos, María-Victoria; Touzeau, Cyrille; Jakubowiak, Andrzej; Usmani, Saad Z.; Cook, Gordon; Cavo, Michele; et al. (Blood, 2022)
Keywords: Aged; Antibodies, Monoclonal - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Clinical Trials and Observations; Female; Humans; Male; Middle Aged; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Neoplasm, Residual - diagnosis; Neoplasm, Residual - drug therapy; Progression-Free Survival; Treatment Outcome